This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Prognosis

Authoring team

Treatment of HCL with purine analogues (cladribine or pentostatin) has demonstrated high rates of complete response (>75%) and prolongation of disease-free survival. However, relapse is reported in approximately 50% of patients in long-term studies. (1)

The promises of new therapies suggest that most patients can now expect to survive for more than 10 years. With previous methods, median survival was 6 years, with only one-third of patients surviving longer than 10 years. (2)

Reference

  1. Else M, Dearden CE, Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015 Dec;28(4):217-29.
  2. Paillassa J, Cornet E, Noel S, et al. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020 May 27;10(5):62.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.